Laryngeal ultrasound helps detect vocal cord polyps
Transcutaneous laryngeal ultrasound shows potential as a noninvasive and accurate...Read more on AuntMinnie.comRelated Reading:
3-month PET/CT helps track oropharyngeal cancer
Just say 'eee' for neck CT
CT, MRI show successful vocal cord restoration
MDCT answers most head and neck questions
MDCT protocols weighed for cancers of larynx, hypopharynx (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 8, 2020 Category: Radiology Source Type: news
Engineered killer immune cells target tumours and their immunosuppressive allies
(eLife) Scientists have engineered natural killer immune cells that not only kill head and neck tumour cells in mice but also reduce the immune-suppressing myeloid cells that allow tumours to evade the immune response, according to a new study in eLife. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news
Comparison of prevalence and associated factors of depressive disorder between patients with head and neck cancer and those with lung cancer at a tertiary hospital in Taiwan: a cross-sectional study - Lee Y, Hung CF, Chien CY, Lin PY, Lin MC, Wang CC, Lu HI, Chen YC, Chong MY, Wang LJ.
This study aimed to compare the prevalence and associated factors of depressive disorder between patients with head and neck cancer (HNC) and those with lung cancer (LC).
DESIGN: This st... (Source: SafetyLit)
Source: SafetyLit - July 5, 2020 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Oncotarget: Bacteriome and mycobiome and bacteriome-mycobiome interactions
(Impact Journals LLC) Volume 11 Issue 25 of @Oncotarget reported that the authors aimed to characterize the bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma, or HNSCC, patients and to determine if they are distinct from those of the oral wash of matched non-Head and neck squamous cell carcinoma patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news
Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Triple-negative bre...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news
FDA Approves Keytruda for Certain Mesothelioma Patients
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week.
Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers.
This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options.
A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - June 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
Gardasil-9 Approved for Prevention of Head and Neck Cancers Gardasil-9 Approved for Prevention of Head and Neck Cancers
The FDA has expanded the indication for the Gardasil-9 vaccine to include the prevention of head and neck cancersMedscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 15, 2020 Category: Primary Care Tags: Hematology-Oncology News Source Type: news
FDA Approves Merck ’s Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
KENILWORTH, N.J.--(BUSINESS WIRE) June 12, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Gardasil 9 for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 15, 2020 Category: Drugs & Pharmacology Source Type: news
What Causes Pyogenic Granulomas?
Discussion
Pyogenic granuloma (PG) is a benign, vascular lesion of the skin. PGs are red, small, often pedunculated nodules that can rapidly increase in size (up to 1-2 cm). They also can often ulcerate and bleed. They frequently occur on the head and neck, with back and chest being the next most common locations but can occur in other locations. They usually are solitary and do not regress. They are seen in children (mean age 6.7 years), young adults and pregnant women (5%). Treatment is electrocautery or excision.
Learning Point PG’s cause is not fully understood. A gene has recently been identified with PG sugge...
Source: PediatricEducation.org - June 15, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
University of Toronto team awarded CIHR grant to study impact of cannabis use on Indigenous oral health
Clinical research and Indigenous knowledge models will help team gather first evidence of effects of cannabis on Indigenous peoples of CanadaUniversity of Toronto - Faculty of DentistryIMAGE: Sacred Indigenous objects laid out on cloth for Learning Circle Symposium, 2018.viewmore Credit: Katia TaylorA multidisciplinary team from the University of Toronto, with experts from the Faculty of Dentistry and the Waakebiness-Bryce Institute for Indigenous Health at the Dalla Lana School of Public Health have been awarded a five year, $1.5 million grant from the Canadian Institutes of Health Research to study the impact o...
Source: Dental Technology Blog - June 10, 2020 Category: Dentistry Source Type: news
Weekly Cisplatin New Standard in Postop Head and Neck Cancer Weekly Cisplatin New Standard in Postop Head and Neck Cancer
In a randomized trial, weekly cisplatin plus radiotherapy has been shown to be not only less toxic than dosing once every three weeks but also achieves better outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
NIDCR's Summer 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Summer 2020 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities
NIH/HHS News
Funding Notices
Science Advances
Subscribe to NICDR News
Grantee News
NIDCR News
NIDCR Announces Availability of COVID-19 Research Funding
On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructure or...
Source: NIDCR Science News - June 4, 2020 Category: Dentistry Source Type: news
FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer ...
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
(University of Texas M. D. Anderson Cancer Center) The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2020 Category: International Medicine & Public Health Source Type: news
FDA approves Roche ’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer
Basel, 19 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of tumour cells [TC ≥ 50%] or PD-L1 stained tumour-infiltrating [IC] covering ≥ 10% of the tumour area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumour aberrations.“We are pleased to offer people with certain types of lung cancer a new chemotherapy-free option ...
Source: Roche Media News - May 19, 2020 Category: Pharmaceuticals Source Type: news
